Literature DB >> 21062911

Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior.

M Kiupel1, J D Webster, K L Bailey, S Best, J DeLay, C J Detrisac, S D Fitzgerald, D Gamble, P E Ginn, M H Goldschmidt, M J Hendrick, E W Howerth, E B Janovitz, I Langohr, S D Lenz, T P Lipscomb, M A Miller, W Misdorp, S Moroff, T P Mullaney, I Neyens, D O'Toole, J Ramos-Vara, T J Scase, F Y Schulman, D Sledge, R C Smedley, K Smith, P W Snyder, E Southorn, N L Stedman, B A Steficek, P C Stromberg, V E Valli, S E Weisbrode, J Yager, J Heller, R Miller.   

Abstract

Currently, prognostic and therapeutic determinations for canine cutaneous mast cell tumors (MCTs) are primarily based on histologic grade. However, the use of different grading systems by veterinary pathologists and institutional modifications make the prognostic value of histologic grading highly questionable. To evaluate the consistency of microscopic grading among veterinary pathologists and the prognostic significance of the Patnaik grading system, 95 cutaneous MCTs from 95 dogs were graded in a blinded study by 28 veterinary pathologists from 16 institutions. Concordance among veterinary pathologists was 75% for the diagnosis of grade 3 MCTs and less than 64% for the diagnosis of grade 1 and 2 MCTs. To improve concordance among pathologists and to provide better prognostic significance, a 2-tier histologic grading system was devised. The diagnosis of high-grade MCTs is based on the presence of any one of the following criteria: at least 7 mitotic figures in 10 high-power fields (hpf); at least 3 multinucleated (3 or more nuclei) cells in 10 hpf; at least 3 bizarre nuclei in 10 hpf; karyomegaly (ie, nuclear diameters of at least 10% of neoplastic cells vary by at least two-fold). Fields with the highest mitotic activity or with the highest degree of anisokaryosis were selected to assess the different parameters. According to the novel grading system, high-grade MCTs were significantly associated with shorter time to metastasis or new tumor development, and with shorter survival time. The median survival time was less than 4 months for high-grade MCTs but more than 2 years for low-grade MCTs.

Entities:  

Mesh:

Year:  2010        PMID: 21062911     DOI: 10.1177/0300985810386469

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  77 in total

1.  Nasal-skin-fold transposition flap for upper lip reconstruction in a French bulldog.

Authors:  Manuel Benlloch-Gonzalez; Stéphanie Lafarge; Bernard Bouvy; Cyrill Poncet
Journal:  Can Vet J       Date:  2013-10       Impact factor: 1.008

2.  Scrotal tumors in dogs: a retrospective study of 676 cases (1986-2010).

Authors:  Michelle C Trappler; Cathy A Popovitch; Michael H Goldschmidt; Kyle H Goldschmidt; Rebecca E Risbon
Journal:  Can Vet J       Date:  2014-01       Impact factor: 1.008

3.  Intramuscular mast cell tumors in 7 dogs.

Authors:  William P Robinson; James Elliott; Stephen J Baines; Laura Owen; Chris J Shales
Journal:  Can Vet J       Date:  2017-09       Impact factor: 1.008

4.  Presumptive primary pulmonary mast cell tumor in 2 dogs.

Authors:  Olivier Campbell; Louis-Philippe de Lorimier; Guy Beauregard; Sébastien Overvelde; Shannon Johnson
Journal:  Can Vet J       Date:  2017-06       Impact factor: 1.008

5.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

6.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

7.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

Review 8.  IIB or not IIB, part 1: retrospective evaluation of Kenney-Doig categorization of equine endometrial biopsies at a veterinary diagnostic laboratory and comparison with published reports.

Authors:  Jane Westendorf; Bruce Wobeser; Tasha Epp
Journal:  J Vet Diagn Invest       Date:  2021-11-28       Impact factor: 1.279

9.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

10.  Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.

Authors:  Jennifer K Hay; Victoria S Larson
Journal:  Can Vet J       Date:  2019-12       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.